Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 rhPSMA - Blue Earth Therapeutics

Next Previous
Drug Profile

Actinium-225 rhPSMA - Blue Earth Therapeutics

Alternative Names: 225Ac-radiohybrid-(rh)PSMA-theranostics; 225Ac-rh PSMA-theranostics; 225Ac-rhPSMA-10.1; 225Ac-rhPSMA; Ac225-rhPSMA

Latest Information Update: 25 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Technical University Munich
  • Developer Blue Earth Diagnostics; Scintomics
  • Class Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 24 Jul 2024 Blue Earth Therapeutics entered into a clinical research collaboration with University College London (UCL) to conduct phase I/II trial for prostate cancer
  • 24 Jul 2024 Blue Earth Therapeutics in collaboration with University College London (UCL) plans a phase I/II trial for Prostate cancer (Metastatic cancer) (Parenteral)
  • 11 Sep 2023 Preclinical development in Prostate-cancer is ongoing in United Kingdom (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top